GL1X · GenesisL1 explorer

MolNFT v1 · #88137 · protein

Crystal structure of human soluble adenylyl cyclase with pyrophosphate

4CLU · Adenylate cyclase type 10: “Crystal structure of human soluble adenylyl cyclase with pyrophosphate”. X-ray diffraction, 3 ligands (POP, MG, CL), 5 pockets (best druggability 0.74). MolNFT v1 #88137 on GenesisL1: 3D structure…

PDB
4CLU
Type
protein
Length
460 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Adenylate cyclase type 10
EC
4.6.1.1
UniProt
Q96PN6
Ligands
POP, MG, CL
Pockets
5 · best druggability 0.74

Structure

x-ray diffraction · 1 distinct chain · 39% helix, 29% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAdenylate cyclase type 10 (EC 4.6.1.1)protein46039% helix, 29% strandQ96PN6

Ligands and binding sites

  • POP · Pyrophosphate 2- · ligand · chains A
  • MG · Magnesium ion · metal · chains A
  • CL · Chloride ion · ion · 2 copies · chains A
  • EDO · 1,2-ethanediol · additive · 4 copies · chains A
  • GOL · Glycerol · additive · chains A
  • ACT · Acetate ion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12660.740.8833CL, EDO
24520.740.8362CL, POP, MG, ACT
31610.680.8727empty
42090.480.7526empty
5620.350.7818GOL, EDO

Modifications

Observed in the structure: 1 modified (artifact).

Compared structures

  • 4CLU · Crystal structure of human soluble Adenylyl Cyclase with pyrophosphate · the same entry in another collection · chain A against A, TM-score 1.00
  • Q96PN6 · AlphaFold monomer V2.0 prediction for adenylate cyclase type 10 (Q96PN6) · a predicted model of the same protein · chain A against A, TM-score 0.95

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.